Split Creek Capital LLC’s United Therapeutics UTHR Stock Holding History

Split Creek Capital LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-426	Closed	-$253K	–	145
2026 Q1	$253K	Sell	426 -58	-12%	-$28.9K	0.27%	105
2025 Q4	$236K	Buy	+484	New	+$225K	0.25%	118

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Split Creek Capital LLC's UTHR Position: Q2 2026 in Review

Split Creek Capital LLC sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 426 shares — an estimated $253K sold.

Split Creek Capital LLC first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $253K in Q1 2026. 886 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Split Creek Capital LLC reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Split Creek Capital LLC sold 426 United Therapeutics shares in Q2 2026, an estimated $253K.
Split Creek Capital LLC first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
Split Creek Capital LLC's United Therapeutics position peaked at $253K in Q1 2026.
886 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Split Creek Capital LLC's 13F filing for Q2 2026, filed 23 Oct 2026.